11-05-2022, 07:58 AM
bwl clarifications -
https://links.sgx.com/FileOpen/2022%2005...eID=716372
The Board wishes to confirm that the outstanding issue faced by the Company is its transition to the direct selling model in China, and there are no on-going investigations into the Group in connection with the aforestated allegations or arising from the findings of the independent review.
... the Board wishes to reiterate that it is still considering a delisting and will be exploring all feasible options to achieve the same, including a delisting under Rule 1309 of the Listing Manual of the SGX-ST.
Gratitude.
https://links.sgx.com/FileOpen/2022%2005...eID=716372
The Board wishes to confirm that the outstanding issue faced by the Company is its transition to the direct selling model in China, and there are no on-going investigations into the Group in connection with the aforestated allegations or arising from the findings of the independent review.
... the Board wishes to reiterate that it is still considering a delisting and will be exploring all feasible options to achieve the same, including a delisting under Rule 1309 of the Listing Manual of the SGX-ST.
Gratitude.